Diaverum returned from the recent EuroPD congress in Poland as an award-winner and with the message that knowledge is key for patients to choose the best treatment for them.
The European Peritoneal Dialysis (EuroPD) congress has, since 1994, grown to become a world-leading forum for the advancement of peritoneal dialysis (PD) treatment and research. Some 1,440 delegates from 60 countries attended this edition of the event in Krakow, Poland, making it the most important PD event on the European calendar.
Dr Janusz Ostrowski, Diaverum PD Director Poland, on his return from the congress, said its more academic lectures and clinic-based reporting “underlined the issue that knowledge concerning PD and proper training is needed to increase PD’s uptake as a treatment modality for chronic kidney disease”.
Poland’s Deputy Medical Director, Dr Anna Bednarek, adds that it was special to note the wider use of PD at the time of acute kidney injury (AKI) as equally as effective as haemodialysis (HD) in terms of patient outcomes. “This is clearly stated as such in the International Society for Peritoneal Dialysis (ISPD) guidelines,” says Dr Bednarek.
Similarly, evidence presented at EuroPD showed the use of PD at the time of congestive heart failure has become encouraging particularly with its impact of reducing patient hospitalisation thereby increasing their quality of life.
Diaverum’s PD team was one of the more active participants at the EuroPD congress. Led by Dr Belén Marrón, Diaverum’s Home Therapies Medical Director, three posters and one oral communication — which was one of only four oral communications selected by the congress — were presented on behalf of 40 co-authors, 30 clinics and 3 countries (Poland, Hungary and Romania).
Dr Marrón’s lecture, ‘Impact of type of referral and dialysis start on clinical outcomes and final RRT in a multicentre-multinational Integrated Care setting’, was striking when considering that despite 80 per cent of incident patients receiving information on available treatment modalities, only 11 per cent used PD.
During the discussion, the use of decision-making tools in Diaverum brought high expectation. Nowadays, this new approach to modality choice provision, as also emphasised during the congress, is considered the gold standard and may be unethical not to follow this structured process with patients — including those with unplanned or urgent dialysis starts.
To end the congress on a high note, Dr Marrón’s presentation was honoured with the award for ‘best oral clinical communication’. Congratulations!